We are live on ! Find out more
OCA

Octagon Capital Advisors Portfolio holdings

AUM $904M
1-Year Est. Return 737.04%
This Fund
S&P 500
This Quarter Est. Return
-15.12%
1 Year Est. Return
+737.04%
3 Year Est. Return
+2,554.78%
5 Year Est. Return
+4,333.84%
10 Year Est. Return
–
AUM
$375M
AUM Growth
-$87.8M
Cap. Flow
-$3.19M
Cap. Flow %
-0.85%
Top 10 Hldgs %
91.67%
Holding
25
New
1
Increased
6
Reduced
8
Closed
5

Top Buys

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$21.8M
2
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$18.8M
3
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$14.1M
4
APLS
Apellis Pharmaceuticals
APLS
+$11.1M
5
RCUS icon
Arcus Biosciences
RCUS
+$4.41M

Top Sells

Rank Stock Value
1
ITOS
iTeos Therapeutics
ITOS
+$14.5M
2
BBIO icon
BridgeBio Pharma
BBIO
+$11.2M
3
NBP
NovaBridge Biosciences American Depositary Shares
NBP
+$10.2M
4
FDMT icon
4D Molecular Therapeutics
FDMT
+$9.08M
5
KROS icon
Keros Therapeutics
KROS
+$8.25M

Sector Composition

Rank Sector Weight
1 Healthcare 95.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APLS
1
DELISTED
Apellis Pharmaceuticals
APLS
$117M 31.17%
2,583,059
+243,000
+10% +$11.1M
RCUS icon
2
Arcus Biosciences
RCUS
$3.57B
$67.7M 18.06%
2,669,974
+180,000
+7% +$4.41M
KDNY
3
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$44.6M 11.91%
2,551,703
+1,195,453
+88% +$18.8M
HZNP
4
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$26.3M 7.02%
330,000
+230,000
+230% +$21.8M
GOSS icon
5
Gossamer Bio
GOSS
$66.5M
$23.1M 6.16%
2,758,069
+194,931
+8% +$1.51M
CLDX icon
6
Celldex Therapeutics
CLDX
$2.77B
$20.5M 5.48%
761,398
– –
XBI icon
7
State Street SPDR S&P Biotech ETF
XBI
$10.1B
$18.1M 4.82%
243,400
+187,600
+336% +$14.1M
STOK icon
8
Stoke Therapeutics
STOK
$1.82B
$10.1M 2.69%
763,456
-50,000
-6% -$760K
BBIO icon
9
BridgeBio Pharma
BBIO
$16.5B
$8.48M 2.26%
933,743
-1,333,743
-59% -$11.2M
VERA icon
10
Vera Therapeutics
VERA
$2.54B
$7.83M 2.09%
575,000
– –
ARVN icon
11
Arvinas
ARVN
$518M
$7.51M 2.01%
178,500
– –
RNAM
12
DELISTED
Avidity Biosciences
RNAM
$4.67M 1.25%
321,641
– –
FDMT icon
13
4D Molecular Therapeutics
FDMT
$526M
$4.42M 1.18%
632,745
-934,150
-60% -$9.08M
KROS icon
14
Keros Therapeutics
KROS
$199M
$4.21M 1.12%
152,249
-187,965
-55% -$8.25M
NBP
15
NovaBridge Biosciences American Depositary Shares
NBP
$205M
$2.26M 0.6%
199,876
-849,815
-81% -$10.2M
IMVT icon
16
Immunovant
IMVT
$8.09B
$2.26M 0.6%
579,061
-895,939
-61% -$3.87M
RXDX
17
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$2.26M 0.6%
80,000
– –
IPSC icon
18
Century Therapeutics
IPSC
$381M
$2.18M 0.58%
260,000
-398,266
-61% -$3.91M
MREO
19
Mereo BioPharma
MREO
$45.9M
$1.12M 0.3%
+1,000,000
New +$775K
AMAM
20
DELISTED
Ambrx Biopharma Inc
AMAM
$325K 0.09%
122,800
-26,600
-18% -$101K
CNTB
21
Connect Biopharma Holdings
CNTB
$135M
– –
-279,921
Closed -$845K
DYN icon
22
Dyne Therapeutics
DYN
$4.04B
– –
-525,284
Closed -$5.06M
ITOS
23
DELISTED
iTeos Therapeutics
ITOS
– –
-450,776
Closed -$14.5M
OMGA
24
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
– –
-176,470
Closed -$1.1M
SURF
25
DELISTED
Surface Oncology, Inc. Common Stock
SURF
– –
-2,300,000
Closed -$6.76M

Similar funds

AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
AOWM
Asset One Wealth Management Bellevue, Washington $904M AUM
SWM
Sendero Wealth Management San Antonio, Texas $904M AUM 22.78% 1-Year Est. Return
EI
EnCap Investments Houston, Texas $905M AUM
PIP
Permian Investment Partners Dallas, Texas $905M AUM 13.43% 1-Year Est. Return
PSCM
Per Stirling Capital Management Austin, Texas $905M AUM 17.06% 1-Year Est. Return
EWM
Evermay Wealth Management Arlington, Virginia $902M AUM 14.76% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

Octagon Capital Advisors's Q2 2022 Portfolio in Review

As of Q2 2022, Octagon Capital Advisors held 25 positions worth $375M, down 19% from $463M the previous quarter. Its ten largest holdings account for 92% of the portfolio.

Octagon Capital Advisors's Q2 2022 filing shows 1 new, 6 increased, 8 reduced and 5 closed positions. Its largest new stake was Mereo BioPharma: 1,000,000 shares worth $1.12M. The largest sale was iTeos Therapeutics, an estimated $14.5M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 99% a quarter earlier.

  • Octagon Capital Advisors's largest Q2 2022 buy was Mereo BioPharma: 1,000,000 shares worth $1.12M.
  • Octagon Capital Advisors added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2022, an estimated $21.8M increase.
  • Octagon Capital Advisors's biggest Q2 2022 reduction was BridgeBio Pharma, cutting an estimated $11.2M.
  • Octagon Capital Advisors fully exited iTeos Therapeutics in Q2 2022, selling an estimated $14.5M.
  • Octagon Capital Advisors's ten largest holdings make up 92% of its $375M portfolio in Q2 2022.
  • Octagon Capital Advisors opened 1 new position and closed 5 in Q2 2022.
  • Octagon Capital Advisors's portfolio value fell 19% quarter-over-quarter to $375M.

Based on Octagon Capital Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.